In Part I and II of this series of articles, the effectiveness treatment initiated at an earlier stage, with either Lupron or Provenge, was compared with the effectiveness of either agent when started at a later stage. With both types of treatment, starting the therapy at an earlier stage resulted in a significant enhancement of the anticancer effects. Similarly, recent studies evaluating the effectiveness of starting Taxotere at an earlier stage show the same thing. READ THE FULL ARTICLE HERE > https://www.verywell.com/treatment-for-metastatic-prostate-cancer-part-iii-3901290